Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial

• DOI: 10.1111/bjh.17119
• Publication Date: 2020-11-10T21:08:33Z
• Authors: Pascale Grégoire‐...; Yves Pastore; Nancy Robitaille; Sylvie LeMay; Ali Khamessan; Niina Kleiber; Carine Nyalendo; Nancy Gagné; Nathalie Alos; Geneviève Mailhot
• Keywords: Bolus (digestion)

Summary Previously, we showed that nearly 70% of children followed in our sickle cell disease (SCD) clinic were vitamin D‐ deficient and had low intake with poor use supplements. We compared the change serum 25‐hydroxyvitamin D [25(OH)D], safety clinical impact two supplementation regimens SCD. Children (5–17 years, all genotypes) randomized to a single bolus 3 (300 000 IU; n = 18) or placebo ( 20). All received prescription for daily 1 IU . Serum 25(OH)D calcium, urinary calcium/creatinine ratio, musculoskeletal pain, quality life, haematology bone markers assessed at baseline three months post intervention. Bolus administration led greater rise levels from (20 ± 16 nmol/l vs. 2 19 nmol/l; P 0·003) correction deficiency. No hypercalcaemia nor hypercalciuria occurred during study, but more group experienced gastrointestinal symptoms within first month 0·04). There no differences between groups other outcomes. The high‐dose combined was efficient raising than alone